Dapagliflozin (BMS-512148) is an orally-available C-aryl glucoside diphenylmethanol inhibitor of SGLT2 (IC50 1.1 nM) for the treatment of Type 1 and Type 2 diabetes. It is the first approved SGLT2 inhibitor (European Union as Forxiga) for the treatment of diabetes. Its excellent selectivity over SGLT1 (IC50 1390 nM) ensures that it does not interfere with intestinal glucose absorption. Dapagliflozin minimally inhibits glucose transporters GLUT1 and GLUT2 and modestly inhibits GLUT4. [1]Dapagliflozin removes excess glucose and its associated calories in urine, which in turn reduces blood sugar levels. Clinical studies have shown concurrent reductions in weight and blood pressure. [2] In combination with metformin, the weight loss was statistically significant, dose-dependent, and persisted for over two years. [3]

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。